FDA Inspections To Target 55% Of “High-Risk” Manufacturers In FY 2004
Executive Summary
FDA inspections will target 55% of "high-risk" drug manufacturers during fiscal year 2004
You may also be interested in...
FDA Plays Up Police Role; “White Paper” Recaps Recent Enforcement Steps
An FDA "White Paper" highlighting the agency's recent enforcement actions is part of a concerted effort to draw consumer, industry and media attention to the agency's role in policing industry
FDA Inspections To Focus On Sterile Rx, New Facilities In FY 2003
FDA will continue to emphasize inspection of sterile manufacturing facilities in fiscal year 2003, Division of Manufacturing & Product Quality Director Joseph Famulare said Dec. 11
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011